Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving hundreds of leading biopharmaceutical companies globally:

UBS
Johnson and Johnson
Citi
McKinsey
McKesson
Federal Trade Commission
Colorcon
Accenture
Chubb

Generated: June 18, 2018

DrugPatentWatch Database Preview

Details for Patent: 5,656,295

« Back to Dashboard

Summary for Patent: 5,656,295
Title: Controlled release oxycodone compositions
Abstract:A method for substantially reducing the range in daily dosages required to control pain in approximately 90% of patients is disclosed whereby an oral solid controlled release dosage formulation having from about 10 to about 40 mg of oxycodone or a salt thereof is administered to a patient. The formulation provides a mean maximum plasma concentration of oxycodone from about 6 to about 60 ng/ml from a mean of about 2 to about 4.5 hours after administration, and a mean minimum plasma concentration from about 3 to about 30 ng/ml from about 10 to about 14 hours after repeated "q12h" (i.e., every 12 hour) administration through steady-state conditions. Another embodiment is directed to a method for substantially reducing the range in daily dosages required to control pain in substantially all patients by administering an oral solid controlled release dosage formulation comprising up to about 160 mg of oxycodone or a salt thereof, such that a mean maximum plasma concentration of oxycodone up to about 240 ng/ml from a mean of up to about 2 to about 4.5 hours after administration, and a mean minimum plasma concentration up to about 120 ng/ml from about 10 to about 14 hours after repeated "q12h" (i.e., every 12 hour) administration through steady-state conditions are achieved. Controlled release oxycodone formulations for achieving the above are also disclosed.
Inventor(s): Oshlack; Benjamin (New York, NY), Chasin; Mark (Manalpan, NJ), Minogue; John Joseph (Mount Vernon, NY), Kaiko; Robert Francis (Weston, CT)
Assignee: Euro-Celtique, S.A. (Luxembourg, LU)
Application Number:08/618,344
Patent Litigation and PTAB cases: See patent lawsuits and PTAB cases for patent 5,656,295
Patent Claim Types:
see list of patent claims
Formulation; Compound; Dosage form; Composition; Use;

Drugs Protected by US Patent 5,656,295

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Patent Submitted
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Patent Submitted

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

International Family Members for US Patent 5,656,295

Country Document Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration
Austria 144418 ➤ Try a Free Trial
Austria 226822 ➤ Try a Free Trial
Austria 261725 ➤ Try a Free Trial
Austria 261726 ➤ Try a Free Trial
Country Document Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

For more information try a trial or see the plans and pricing

Serving hundreds of leading biopharmaceutical companies globally:

Daiichi Sankyo
Covington
Medtronic
UBS
QuintilesIMS
Teva
Harvard Business School
Johnson and Johnson
Argus Health

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.